The global pain management market continued to demonstrate strong growth in 2007, despite patent expiries of leading products and strong generic competition. The NSAIDs segment of the market has overcome the impact of an FDA-imposed black box warning in 2005, however the local anesthetics market is facing significant generic penetration as the FDA has relaxed the requirements for the approval of the generic Lidoderm.

‘The Pain Management Market Outlook to 2014’ provides comprehensive coverage of major markets within the global pain management area, incorporating a epidemiological analysis of key neuropathic and nociceptive pain indications and the main factors impacting their prevalence. Current leading brands of treatment within each indication are analysed with sales data from H1 2008 and the top ten leading players of the market are examined in detail. This report reviews the factors and underlying trends that are shaping the pain management market and identifies the most promising areas of potential growth. Forecasts for currently marketed and key pipeline products over the 2009-14 period are also provided.

Key Findings

• The global pain management market generated $46.4bn sales in 2007, a 12.5% increase over 2006.
The most prevalent forms of neuropathic pain in the seven major markets were neuralgia/fibromyalgia and lower back pain, with 16.3m and 15.9m cases respectively during 2008.

• Analgesics (narcotics and non–narcotics) account for 43% of the global pain management market,
having generated revenues of $19.9bn in 2007. The segment also demonstrated robust 15.2% growth y–o–y.
Narcotics segment is dominated by Mundipharma’s OxyContin CR, while the highly fragmented non–narcotic segment is led by BMS’ Efferalgan and J&J’s Tylenol.

• Pfizer was the leading player in the pain management market in 2007 with sales of $5.5bn, a 14.6% increase over 2006. Celebrex registered sales of

• Orexo AB's and Prostraken’s Rapinyl/Abstra and King's and Durect’s Eladur are the most promising
advanced formulations to recently enter Phase III trials. Rapinyl/Abstral is intended for breakthrough
cancer pain and Eladur is the first bupivacaine formulation to receive orphan status from the FDA.

Use this report to...

• Assess patient potential, treatment trends and sales patterns of major pain indications
over the period 2008-14, with this report’s coverage of neuropathic and nociceptive pain sub-categories across Japan, France, Germany, Italy, Spain, the UK and the US.

• Understand the market dynamics of the global pain management market with this report’s analysis of major drug classes and regional trends, and understand the impact of recent events by assessing key market issues and growth drivers.

• Compare the market performance and strategic positioning of major pharma companies’ pain management portfolios as of H1 2008 with this report’s evaluation of the franchises of Pfizer, J&J, Novartis, GSK Mundipharma, Abbott, Sanofi-Aventis, UCB, Teva and Endo Pharma.

• Forecast sales for key currently marketed pain management therapies as well as leading pipeline products over the period 2008–14, assess the latest trends influencing R&D and evaluate leading developmental products and new chemical entities. $2.3bn, followed by Lyrica with $1.9bn. Together these brands accounted for 75.5% of Pfizer’s overall sales in 2007.

Explore issues including...

M&A activity fuels market growth. Several in/out–licensing deals have occurred recently between major drug firms and specialty pharma companies. There have also been deals between pharmaceuticals and drug delivery specialists.

Generic presence rising. Despite a lack of patent protected brands with sizeable commercial prospects, generic penetration is significant in the global pain management market. There are also a large number
of advanced formulations which do not command premium pricing.

Reduced R&D expenditure. There is an emerging trend focused upon line extensions and expanded formulations. This has enticed specialty pharma and drug delivery companies, who focus on the development of novel dosage forms of existing patent expired products and niche therapies.

Market entry of biologics. The use of biologics in pain management will significantly change the landscape of the market in the future, due to existing pain therapies carrying considerable side-effect profiles. Pfizer is developing the first ever biologic to be used in pain management, tanezumab, a monoclonal antibody that delivers targeted action.

Discover...

• What will be the major growth indications in the pain management market over 2009–14?
• What are the current trends within the major therapy areas of neuropathic and nociceptive pain across the seven major markets?
• What are the most promising compounds currently in clinical development for major pain indications?
• What is the forecast commercial potential of these products through to 2014?
• Which companies are best positioned to succeed in the pain management market over 2009–14?
• What is the forecast market size and growth rate over the period 2009–14 across the pain management market?
• What are the significant market and pipeline developments that may shape the corporate strategies of leading companies?